FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used in treating haematological malignancies. Applications according to the invention relate to (S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chlor-2-phenylisoquinoline-1(2H)-one or its pharmaceutically acceptable form, alone or in combination with one or more other therapeutic agents for the manufacture of a medicament. Method of the invention refers to treating an individual with a hematologic malignant tumour with a therapeutically effective amount of (S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinoline-1(2H)-one or a pharmaceutically acceptable form thereof.
EFFECT: use of inventions enables treating tumours resistant to Brutton tyrosine kinase inhibitors.
58 cl, 21 tbl, 42 dwg, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| COMBINATION THERAPY | 2017 |
|
RU2754507C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| METHODS FOR TREATMENT OF LYMPHOMA | 2019 |
|
RU2784243C2 |
| METHODS AND COMBINED THERAPEUTIC PRODUCT FOR THE TREATMENT OF BILE DUCTS CANCER | 2019 |
|
RU2793543C2 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| COMBINATION OF PIK3 INHIBITOR AND INHIBITOR C-MET | 2013 |
|
RU2705095C2 |
| USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS | 2009 |
|
RU2519200C2 |
| CHEMICAL COMPOUNDS | 2014 |
|
RU2644769C2 |
